# CHANGE THEIR JOURNEY

## IN X-LINKED HYPOPHOSPHATAEMIA (XLH)



#### Abbreviated Package Insert of CRYSVITA Solution for Injection 10 mg/1mL, 20 mg/1mL, or 30 mg/1mL

Abbreviated Package Insert of CRYSVITA Solution for Injection 10 mg/fmL, 20 mg/fmL, or 30 mg/fmL or 30 mg/fmL or 30 mg/fmL. Composition: Burosumab. Indication: Treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 yr of age and older. Dosage & Administration: Pediatric: BW<10 kg: 1 mg/kg (rounded to the nearest 1 mg), administered q2w. BW>10 kg: starting dose is 0.8 mg/kg (rounded to the nearest 10 mg), administered q2w. The starting dose should between 10 to 90 mg. Dose may be increased to ~2mg/kg (max 90 mg), administered q2w to achieve normal serum! P. Adult: 1 mg/kg (rounded to the nearest 10 mg), max dose: 90 mg), administered q4w. Contraindications: Concomitant use with ophosphate & for active vit D analogs due to the risk of hyperphosphatemia; serum phosphorus is within/above the normal range for age; severe renal impairment/ESRD due to abnormal mineral metabolism. Precautions: Hypersensitivity; hyperphosphatemia & risk of nephrocalcionsis; injection site reactions; Pregnancy & lactation; Pediatric: 4 yr of age; Elderly, Renal impairment. Common adverse reactions: For pediatric: pyrexia; injection site reactions, cough, vomiting; pain in extremity; headache; tooth abscess; dental caries. For adults: back pain; headache; tooth infection; restless leg syndrome; vitamin D decreased; dizziness; constipation; muscle spasms; increase serum P. Interaction: Oral phosphate and active vit D analogs. P/P: Injection: 10 mg/mL, 20 mg/mL, or 30 mg/mL in a single-dose vial. Approved version of package insert: Jan 2020
Please refer to the full prescribing information before prescribing. Further information is available upon request.







# CHANGE THEIR JOURNEY

## IN X-LINKED HYPOPHOSPHATAEMIA (XLH)



#### Abbreviated Package Insert of CRYSVITA Solution for Injection 10 mg/1mL, 20 mg/1mL, or 30 mg/1mL

Abbreviated Package Insert of CRYSVITA Solution for Injection 10 mg/fmL, 20 mg/fmL, or 30 mg/fmL, or 30 mg/fmL adentified in Eurosumab. Indication: Treatment of X-Linked hypophosphatemia (XLH) in adult and pediatric patients 1 yr of age and older. Dosage & Administration: Pediatric: BW<10 kg: 1 mg/kg (rounded to the nearest 1 mg), administered q2w. BW>10 kg: starting dose is 0.8 mg/kg (rounded to the nearest 10 mg), administered q2w. The starting dose should between 10 to 90 mg. Dose may be increased to ~2mg/kg (max 90 mg), administered q2w to achieve normal serum P. Adult: 1 mg/kg (rounded to the nearest 10 mg, max dose: 90 mg), administered q4w. Contraindications: Concomitant use with oral phosphate &ior active vit D analogs due to the risk of hyperphosphatemia; serum phosphorus is within/above the normal range for age; severe renal impairment/ESRD due to abnormal mineral metabolism. Precautions: Hypersensitivity; hyperphosphatemia & risk of nephrocalcinosis: injection site reactions; Pregnancy & leadation; Pediatric: 4 yr of age; Edderly, Renal impairment. Common adverse reactions: For gediatric: pyrexia; injection site reactions, cough, vomiting; pain in extremity; headache; tooth abscess; dental caries. For adults: back pain; headache; tooth infection; restless leg syndrome; vitamin D decreased; dizziness; constipation; muscle spasms; increase serum P. Interaction: Oral phosphate and active vit D analogs. P/P: Injection: 10 mg/mL, 20 mg/mL, or 30 mg/mL in a single-dose vial. Approved version of package insert. Jan 2020
Please refer to the full prescribing information before prescribing. Further information is available upon request.



